Ad
Wednesday, 28 March 2018
Teva wins reversal of U.S. jury's $235 million GSK drug patent verdict
(Reuters) - A federal judge on Wednesday overturned a U.S. jury's verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment